High Tower Advisors, LLC Zentalis Pharmaceuticals, Inc. Transaction History

High Tower Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$16.14 - $24.94 $4,341 - $6,708	-269 Reduced 0.89%	29,905 $514,000
Q4 2022 Feb 08, 2023	BUY	$18.07 - $25.6 $4,463 - $6,323	247 Added 0.83%	30,174 $607,000
Q3 2022 Nov 09, 2022	SELL	$20.23 - $31.73 $5,886 - $9,233	-291 Reduced 0.96%	29,927 $648,000
Q2 2022 Aug 10, 2022	SELL	$17.91 - $52.25 $447 - $1,306	-25 Reduced 0.08%	30,218 $848,000
Q1 2022 May 12, 2022	SELL	$41.58 - $80.89 $790 - $1,536	-19 Reduced 0.06%	30,243 $1.4 Million
Q4 2021 Feb 10, 2022	BUY	$66.92 - $84.79 $23,890 - $30,270	357 Added 1.19%	30,262 $2.54 Million
Q2 2021 Aug 06, 2021	BUY	$37.41 - $62.25 $1.12 Million - $1.86 Million	29,905 New	29,905 $1.59 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $170M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on High Tower Advisors, LLC with notifications on news.